Advertisement

Topics

Pro-Trader Daily: Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations

07:45 EDT 14 Sep 2017 | FinanzNachrichten

Research Desk Line-up: China Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

Original Article: Pro-Trader Daily: Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations

NEXT ARTICLE

More From BioPortfolio on "Pro-Trader Daily: Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations"

Quick Search
Advertisement